TSXV:HEM - Post Discussion
Post by
henery345 on Jun 10, 2022 12:21pm
$HMTXF get backs all its intellectual property
Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trial data, all historical data from Hemostemix Israel, and the randomization tables that are required to analyze the North American and South African ACP-01 clinical trial data.
https://www.newsfilecorp.com/redirect/VmKbBSxmVP
Be the first to comment on this post